Evidence map›Paper›PMID 27658740›Full record

ArticleHIV clinical trials2016

Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study.

Jordan E Lake, Sophie Seang, Theodoros Kelesidis, Judith S Currier, Otto O Yang

Open access · greenAbstract read

In one paragraph

Article in HIV clinical trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it

0cells of the map it votes in

4citing papers in PubMed

0.7field-weighted citation impact, top 25% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

Coronary Vasculature and Myocardial Structure in HIV: Physiologic Insights From the Renin-Angiotensin-Aldosterone System.The Journal of clinical endocrinology and metabolism · 2021
Review
Immunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIV.Current HIV/AIDS reports · 2020
Review
Low Levels of Endothelial Progenitor Cells and Their Association with Systemic Inflammation and Monocyte Activation in Older HIV-Infected Men.AIDS research and human retroviruses · 2018
Article
HIV Infection and Risk of Cardiovascular Diseases Beyond Coronary Artery Disease.Current atherosclerosis reports · 2017
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jordan E Lakea Division of Infectious Diseases, Department of Medicine , University of California , Los Angeles , CA , USA.

Sophie Seanga Division of Infectious Diseases, Department of Medicine , University of California , Los Angeles , CA , USA.

Theodoros Kelesidisa Division of Infectious Diseases, Department of Medicine , University of California , Los Angeles , CA , USA.

Judith S Curriera Division of Infectious Diseases, Department of Medicine , University of California , Los Angeles , CA , USA.

Otto O Yanga Division of Infectious Diseases, Department of Medicine , University of California , Los Angeles , CA , USA.

University of California, Los Angeles · USAIDS Healthcare Foundation · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015

$57.0M

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018

$39.9M

UCLA OLDER AMERICANS INDEPENDENCE CENTERP30AG028748 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REUBEN, DAVID B. · 2006 to 2017

$9.8M

Inflammation, Fibrosis and End-Organ Disease in HIV-Infected AdultsK23AI110532 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LAKE, JORDAN E · 2014 to 2018

$937k

Oxidized HDL in the intersection of HIV, immune activation and atherosclerosisK08AI108272 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2013 to 2017

$915k

NCATS NIH HHS UL1 TR000124NIAID NIH HHS K08 AI108272NIAID NIH HHS K23 AI110532NIAID NIH HHS P30 AI028697NIA NIH HHS P30 AG028748

6 · The paper itself

Abstract

backgroundEndothelial progenitor cells (EPCs) are bone marrow-derived cells that contribute to vascular repair. EPCs may be reduced in HIV-infected (HIV+) persons, contributing to cardiovascular disease (CVD). Telmisartan is an angiotensin receptor blocker that increases EPCs in HIV-uninfected adults.

objectiveTo assess telmisartan's effects on EPC number and immunophenotype in older HIV + adults at risk for CVD.

methodsHIV + persons ≥50 years old with HIV-1 RNA < 50 copies/mL on suppressive antiretroviral therapy and ≥1 CVD risk factor participated in a prospective, open-label, pilot study of oral telmisartan 80 mg daily for 12 weeks. Using CD34 and CD133 as markers of early maturity and KDR as a marker of endothelial lineage commitment, EPCs were quantified via flow cytometry and defined as viable CD3

resultsSeventeen participants (88% men, median age 60 years and peripheral CD4

conclusionsOur data suggest that telmisartan use is associated with an increase in circulating EPCs in older HIV + individuals with CVD risk factors. Further controlled studies are needed to assess whether EPC increases translate to a reduction in CVD risk in this population.

Indexed as

AgedAngiotensin II Type 1 Receptor BlockersAntiretroviral Therapy, Highly ActiveBenzimidazolesBenzoatesBiomarkersCardiovascular DiseasesCD4 Lymphocyte CountCell CountEndothelial Progenitor CellsFemaleHIV InfectionsHumansMaleMiddle AgedPhenotypeAngiotensin II Type 1 Receptor BlockersBenzimidazolesBenzoatesBiomarkersTelmisartanEndothelial dysfunctionEndothelial progenitor cellsHIVTelmisartan

Identifiers

PMID27658740

DOI10.1080/15284336.2016.1234222

PMCPMC5470589

OpenAlexW2521637274

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.